Dimerization of HIV-1 protease (PR) subunits is an essential process for PR's acquisition of proteolytic activity, which plays a critical role in the maturation of HIV-1. Recombinant wild-type PR (PR   WT   ) proved to dimerize, as examined with electrospray ionization mass spectrometry; however, two active site interface PR mutants (PR T26A and PR
R87K
) remained monomeric. On the other hand, two termini interface PR mutants (PR 1-C95A and PR 97/99 ) took both monomeric and dimeric forms. Differential scanning fluorimetry indicated that PR 1-C95A and PR 97/99 dimers were substantially less stable than PR WT dimers. These data indicate that intermolecular interactions of two monomers occur first at the active site interface, generating unstable or transient dimers, and interactions at the termini interface subsequently occur, generating stable dimers. Darunavir (DRV), an HIV-1 protease inhibitor, inhibits not only proteolytic activity but also PR dimerization. DRV bound to protease monomers in a one-to-one molar ratio, inhibiting the first step of PR dimerization, whereas conventional protease inhibitors (such as saquinavir) that inhibit enzymatic activity but not dimerization failed to bind to monomers. DRV also bound to mutant PRs containing the transframe region-added PR (TFR-PR D25N and TFR-PR ), whereas saquinavir did not bind to TFR-PR D25N or TFR-PR . Notably, DRV failed to bind to mutant PR containing four amino acid substitutions (V32I, L33F, I54M, and I84V) that confer resistance to DRV on HIV-1. To our knowledge, the present report represents the first demonstration of the two-step PR dimerization dynamics and the mechanism of dimerization inhibition by DRV, which should help design further, more potent novel PIs.
AIDS | thermal stability | two-step dimerization dynamics | protease precursor D imerization of HIV-1 protease (PR) subunits is an essential process for the acquisition of proteolytic activity of PR, which plays a critical role in viral maturation in the replication cycle of HIV-1 (1, 2). Thus, PR dimerization inhibition is likely to abolish proteolytic activity and should serve as a promising target for HIV-1 intervention. Structurally there are two interfaces, which operate in the efficient PR dimerization. One is the termini interface, and the other is the active site interface (3, 4) . The termini interface comprises four antiparallel β-sheets involving the first four amino-and carboxy-termini residues of both subunits. Todd et al. (5) have reported that the binding force generated by the termini interface contributes close to 75% of the entire dimerization energy. Indeed, Ishima and others have demonstrated that three amino acid substitutions (T26A, D29N, and R87K), located at the active site interface, together with C-terminal truncation of four amino acids (96-99), effectively disrupted PR dimerization as examined with NMR spectroscopy (Fig. 1) (6-8) . Various groups have tried to target the termini interface in an attempt to intervene HIV-1 replication (9-12); however, none of such efforts to disrupt the termini interface interactions have led to clinical applications. On the other hand, the most recently US Food and Drug Administration (FDA)-approved PR inhibitor (PI), darunavir (DRV), is (to our knowledge) the first to be shown to block the dimerization of HIV-1 PR, as examined with the intermolecular FRET-based HIV-expression assay ( Fig. S1 ) (13) . Furthermore, a combination of four amino acid substitutions in the proximity of the active site interface (V32I/L33F/I54M/I84V), which emerged in PR when HIV-1-infected individuals were heavily treated with multiple PR inhibitors (PIs) and failed such treatment and when HIV-1 was selected in vitro in the presence of increasing concentrations of DRV (14) , has been shown to decrease the dimerization inhibition activity of DRV ( Fig. 1 and Fig. S1B ) (15) . However, the dynamics of dimerization of PR subunits, as well as the molecular mechanism of DRV inhibition of PR dimerization, remain to be elucidated.
Here we generated a variety of recombinant PR species with various amino acid substitution(s) and/or deletions introduced Significance Dimerization of HIV-1 protease (PR) plays a critical role in the replication of HIV-1. Darunavir (DRV) inhibits not only proteolytic activity but also PR dimerization. The present study shows that PR dimerization process undergoes two steps and that DRV inhibits the first step of PR dimerization by binding to PR monomers in a one-to-one molar ratio. The present study also demonstrates that DRV binds to a transframe precursor PR protein, indicating that DRV's monomer binding is involved in the Gag-Pol autoprocessing inhibition. To our knowledge, the present report represents the first demonstration of the twostep PR dimerization dynamics and the mechanism of dimerization inhibition by DRV, which should help design further, more potent novel PR inhibitors. and examined whether such mutated PR species interacted and dimerized using electrospray ionization mass spectrometry (ESI-MS) (16, 17) . We also asked how PIs, including DRV, interacted with such various PR species and blocked the dimerization of PR subunits. The present data demonstrate that intermolecular interactions of two monomers occur first at the active site interface, generating weakly dimerized subunits (transient dimers), and that interactions at the termini interface subsequently occur, generating stable dimers. The ESI-MS data also show that DRV binds to PR monomers in a one-to-one molar ratio and inhibits the first step of PR dimerization, whereas conventional PIs (such as saquinavir) fail to bind to monomers. To our knowledge, the present report should represent the first demonstration of the two-step PR dimerization dynamics and the mechanism of dimerization inhibition by DRV.
Results
The ESI-MS spectra of PR WT and PR D25N revealed four peaks of differently charged ions in the range of mass/charge ratio (m/z) of 1,500-2,500 ( Fig. 2 A and B) . Because +5 charged monomer ion and +10 charged dimer ion have the same m/z (m/z = 2,164.77 as calculated with their average mass in the case of PR D25N ), the greatest peak detected at m/z 2,164. ), respectively, as shown in Fig. S3 C and E.
We also constructed three mutated PR species containing amino acid substitutions at the active site (PR D29N , PR T26A , and PR
R87K
), a C terminus-truncated mutant (PR in Fig. 2A , the PR 1-C95A and PR 97/99 species were thought to have a significantly reduced but persistent ability to dimerize in comparison with PR WT . Taken together, the data strongly suggest that the PR dimerization process consists of two distinct steps: (i) initial albeit weak intermolecular interactions occurring in the active site interface, constructing unstable or transient dimers, and (ii) subsequent interactions in the termini interface, resulting in the complete and tighter PR dimerization (Fig. 4) .
In an attempt to examine the thermal stability of PR WT and various mutated PR species mentioned above, we conducted (Fig. 4) .
We previously reported that DRV inhibits not only proteolytic activity but also PR dimerization, whereas two FDA-approved anti-HIV-1 drugs, saquinavir (SQV) and nelfinavir (NFV), have no dimerization inhibition activity as examined with the FRETbased HIV-1 expression system (Fig. S1A) (13) . To analyze the mechanism of the PR dimerization inhibition by DRV, we therefore examined the binding properties of DRV, SQV, and NFV with PR WT (Fig. 6 A-D (Fig. 6B ). Additional analysis of the isotopologue ion peaks with PR D25N in the presence of DRV confirmed the identity of monomer and dimer ions, as shown in Fig. S3 F-I (Fig. 6D) . The relatively weak intensity of SQV-and NFV-bound PR WT dimers is presumably due to their relatively low binding affinity to PR WT , as previously demonstrated by Dierynk et al. (22) . Taken together, these data indicate that SQV and NFV bind to PR WT dimers but not to monomers, and DRV inhibits PR dimerization by binding to PR monomers in a one-to-one molar ratio.
Highly DRV-resistant HIV-1 isolates we previously generated in vitro (14) had acquired a unique combination of four amino acid substitutions (V32I/L33F/I54M/I84V), and DRV had decreased its binding to PR monomers containing such four amino acid substitutions (Fig. S1B) (14, 15) . We therefore examined whether such four amino acid substitutions altered the binding profiles of DRV with PR, using ESI-MS. The ESI-MS spectrum of PR 32/33/54/84 refolded in the absence of DRV showed four , was detected at m/z 2,230.05, and no DRV-bound PR monomers were detected (Fig. 3B) (Fig. 3C) (Fig. 3D) . Thus, L97 and F99 are not critical for DRV's monomer binding. The present data showed that the current ESI-MS method we used in this study is useful in detecting DRV's specific binding to PR WT . Finally, we asked whether DRV had an ability to bind to the PR precursor protein, Gag-Pol polyprotein, which is produced through the frame-shifting process in the Gag-encoding gene translation (Fig. S5 A and B) and subsequently maturates after the due excision through autoproteolysis (23) (24) (25) (26) . To examine the DRV binding to the PR precursor protein, a transframe precursor form of PR containing D25N substitution, TFR-PR D25N , was constructed (Fig. S5C) (Fig. 3F) , indicating that DRV bound to TFR-PR D25N monomers. In this regard, Agniswarmy et al. (27) have shown that the addition of C terminus four amino acids (PISP) to TFR-PR increases thermal stability of DRV-bound TFR-PR. In the present study we generated TFR-PR , which contained an additional seven N terminus amino acids of reverse transcriptase (7AA; PISPIET) at the C terminus of TFR-PR D25N . The ESI-MS revealed that TFR-PR formed dimers (Fig. S6A) , suggesting that the addition of the seven amino acids allowed TFR-PR D25N-7AA to dimerize, probably by giving TFR-PR D25N-7AA proper conformation. The ESI-MS then showed that DRV binds to both TFR-PR D25N-7AA monomers and dimers (Fig. S6B) . These results strongly suggest that the loss of dimerization ability of TFR-PR D25N resulted in the loss of DRV's dimer binding.
Discussion
In the present study we constructed three "active site interface PR mutants" (PR T26A , PR D29N , and PR R87K ) and two "termini interface PR mutants" (PR (Figs. 2F and 3C). These findings suggest that the dimers represent small components in the three mutated PR species. However, as assessed using the FRET-based HIV-1 expression assay, PR D29N dimerization was apparently completely disrupted (13) . Of particular note, the FRET-based system determines the FRET signal (CFP fluorescence after photobleaching/CFP fluorescence before photobleaching: CFP A/B ratio) in one cell at one time, accumulates ∼20-30 cells' data, and obtains the average of the CFP A/B ratios. Then, if the average value is greater than 1.0, it is judged that FRET occurred, indicating that PR dimerization took place within the cell. However, there is variability in the CFP A/B ratios within the assay data, probably due to, but not limited to (i) unequal expression of PR proteins; (ii) uneven occurrence of protein-protein interactions (i.e., dimerization); and (iii) differing compartmentalization of the expressed PR species within the transfected cell population. Nevertheless, the FRET-based HIV-1 expression assay system only calls whether FRET occurred or did not occur. Thus, the FRET-based HIV-1 expression assay system inherently fails to identify the presence of a small amount of dimers or monomers. Therefore, in the case of PR D29N , the FRET signal was determined as "not detected" (13) . However, the ESI-MS system we used in the present study directly and more quantitatively identifies PR monomers and dimers. Thus, the ESI-MS system correctly recognized both a major fraction of PR D29N monomers as well as a minor fraction of PR D29N dimers. Accordingly, increasing the expression of PR D29N by increasing the amount of plasmid for transfection does not increase the specific FRET-based signal, which we have confirmed in our initial conditioning phase of the construction of the system. Both PR T26A and PR R87K failed to dimerize as examined with the FRET-based HIV-1 expression assay, and no dimerized PR species were seen in the ESI-MS spectra (Fig. S4 and Table S1 ). When we examined the ESI-MS spectra of PR 1-C95A and PR 97/99 , the peaks of +6 charged monomer ions were much greater than in the PR WT spectrum; however, PR dimer species were also present (Figs. 2F  and 3C) . Moreover, DSF analysis showed that PR 1-C95A and PR 97/99 dimers were unstable (Fig. 5 ). Taking these data together, it is strongly suggested that the PR dimerization process undergoes two steps: (i) initial albeit weak intermolecular interactions occurring in the active site interface, and (ii) subsequent interactions occurring in the termini interface, resulting in the complete and tight PR dimerization (Fig. 4) .
In the present study, we also demonstrated that DRV binds to PR WT monomers as well as dimers, whereas other "conventional" PIs, including SQV and NFV, bind only to dimers (Fig. 6 A-D) , confirming that DRV uniquely has dual activity against PR WT : inhibition of PR WT dimerization and proteolytic activity as previously described (13) . It is also noteworthy that the present data clearly showed that DRV binds to PR WT monomer subunit in a one-to-one molar ratio.
We have previously selected highly DRV-resistant HIV-1 variants (HIV DRV R ) and identified that HIV DRV R had acquired a unique combination of four amino acid substitutions (V32I/ L33F/I54M/I84V) in the proximity of the active site interface of its PR (Fig. 1) (14) . In the present data DRV virtually completely failed to bind to PR 32/33/54/84 monomers, and only a small amount of DRV-bound PR 32/33/54/84 dimers was identified (Fig. 3B ). However, L97A and F99A substitutions did not affect DRV's monomer and dimer binding (Fig. 3D) . These results indicate that the binding domain in PR monomers for DRV is located distantly from the termini interface and is close to the active site interface, in line with the results of computational results reported by Huang et al. (28) . Thus, the present ESI-MS analysis results strongly suggest that DRV blocks the first step of the PR dimerization process involving the active site interface, by binding to PR monomers in a one-to-one molar ratio (Fig. 4) .
We have shown that once stable PR WT dimers are formed, DRV no longer disrupts the dimers, as examined using the FRET-based assay (13) . To ask whether DRV's binding to PR WT monomers yields sufficient force to block PR WT dimerization, the determination of the binding affinity of DRV for the folded monomers seems to be technically highly challenging. However, the present ESI-MS data showed that the amount of DRVbound PR WT monomers seemed to be greater than that of DRVbound PR WT dimers (Fig. 6B) . Moreover, we determined the thermal stability of DRV-bound PR WT , which apparently contains more DRV-bound PR WT monomers than DRV-bound PR WT dimers (Fig. 6B ). As illustrated in Fig. S7 , PR WT was found to be highly stable as examined using the differential scanning fluorimetry (DSF), strongly suggesting that DRV fairly strongly binds to PR WT monomer. The DSF data also suggested that DRV's binding to PR WT monomers should have sufficient force to block PR WT dimerization, inhibiting the formation of transient dimers. It is of note that if the formation of transient dimers (first step of the dimerization process) is blocked by DRV, the formation of stable dimers through the termini interface interactions (second step of the dimerization step) no longer occurs (Fig. 4) . The determination of the exact binding site of PR monomer for DRV awaits further investigation, such as crystallographic analysis of PR monomer complexed with DRV and other dimerization inhibitors (13, 29, 30) .
Louis et al. (24) have recently demonstrated that among nine FDA-approved PIs, DRV and SQV most potently block the autoproteolytic processing of the precursor construct (TFR-PR). Davis et al. (26) also demonstrated that among six FDA-approved HIV-1 PIs, DRV and SQV most potently block the initial step of autoproteolytic processing of Gag-Pol polyprotein by embedded dimerized PR. These data strongly suggest that DRV and SQV bind to TFR-PR, although the dynamics of the DRV binding remain elusive (26) . In the present work DRV bound to TFR-PR D25N-7AA monomers and dimers ( Fig.  S6 A and B) , in line with the data by Louis et al. (24) , and our data strongly suggest that DRV blocks the autoproteolytic processing of Gag-Pol polyproteins through binding to the PR precursors (monomers and dimers) within the Gag-Pol polyprotein, contributing to DRV's potent antiretroviral activity against HIV-1. As for SQV, which has a greater K D value (1.2 × 10 −9 M) for binding to PR WT than DRV (4.1 × 10 −13 M) (22), Sayer and Louis (31) have shown that D25N substitution substantially decreases SQV's binding affinity to PR. Indeed, the present ESI-MS data also showed that SQV fails to bind to PR D25N , TFR-PR
D25N
, and TFR-PR D25N-7AA ( Fig. S6C and S8 A-C). Thus the levels of SQV binding to these PR mutants carrying D25N substitution do not seem to be sufficient to be detected by ESI-MS.
A few groups have reported PR dimerization inhibitors targeting the terminal interface of PR (9) (10) (11) (12) . However, none of such inhibitors have been of clinical utility, probably because PR dimers, once formed, are highly stable to "de-dimerize" with the potent dimerization forces in the termini interface (13) . On the other hand, the active site interface interactions play a critical role for PR dimerization, but the dimers formed are thought to be relatively unstable. Thus the development of new dimerization inhibitors targeting the active site interface would be highly suitable. It is also noteworthy that the ESI-MS approach is more quantitative than the FRET-based HIV-1 expression system, and we demonstrated two features: (i) DRV binds to PR WT monomers and dimers, whereas (ii) DRV binds only to TFR-PR D25N monomers. Thus, ESI-MS analysis is useful in analyzing how PR monomers and dimers act in the presence or absence of dimerization-targeting drugs. The new findings demonstrated in the present study should help understand the mechanism of HIV-1 PR inhibition and should also help develop novel and more potent PIs.
Materials and Methods
Vector Construction. The expression vectors containing the HIV-1 PR gene (pET-TFR-PR NL4-3 , pET-PR NL4-3 , and pET-PR 1-C95A ) were constructed by using the In-Fusion HD Cloning Kit (Clontech 
